TS-062688 — Conditioned neutrophils and cell therapy vectors for nerve regeneration

TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…

TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…

TS-062261 — The Need: Addressing the Zika Virus Outbreak The Zika virus outbreak, which started in South America and quickly became a global public health issue, has led to severe neurological disorders, birth defects, and other health complications in affected populations. Despite efforts to combat the virus,…

TS-037747 — A novel peptide therapeutic AAC2 comprising amino acids with a coumarin-modified side chain that improves glucose control and reduces neurological decline and anxiety through activation of the insulin-insensitive glucose transporter 1 (GLUT1).